Pharmaceuticals & Biotechnology
AstraZeneca is a global biopharmaceutical company focused on discovering, developing and commercialising prescription medicines. Its portfolio is concentrated in oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases and other specialist medicines.
Research and development, clinical trials, regulatory submissions, manufacturing and global commercialisation of prescription medicines, with major franchises in cancer treatments, rare diseases, respiratory medicine and cardiovascular, renal and metabolic therapies.
A global business with major sales in the United States, Europe, China and other international markets. The US is particularly important for revenue and profitability, while China remains a significant but more policy-sensitive market.
Drug launches, clinical-trial results, regulatory approvals, patent life, treatment uptake, pricing and reimbursement, pipeline productivity, acquisitions and licensing deals, manufacturing capacity and progress toward the group's long-term revenue ambitions.
Clinical trial failures, regulatory setbacks, loss of patent exclusivity, pricing pressure, litigation, competition from new therapies and generics, manufacturing issues, large R&D commitments and policy or procurement changes in major healthcare markets.
27 July 2026: first-half revenue rose 9% to $30.7bn and core EPS increased 12%. Growth in Oncology and Rare Disease offset headwinds from Farxiga's US loss of exclusivity and Chinese procurement changes, while full-year guidance was reaffirmed.
Normally pays twice yearly under a progressive policy. The 2026 first interim is $1.06 per share, ex-dividend on the LSE on 6 August 2026 and payable 8 September. The 2025 second interim of $2.17 went ex-dividend on 19 February and was paid on 23 March.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.